Results 51 to 60 of about 312,775 (324)

Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study [PDF]

, 2018
Background: Few studies have compared the efficacy of switching to adalimumab in the real-life setting in plaque psoriasis patients. Objective: To evaluate the effect of adalimumab in psoriasis patients previously treated with other biologics.
Armesto, Burmester, Carrera, Davison, Edson-Heredia, Elm, Gisondi, Gisondi, Gisondi, Gordon, Gossec, Gossec, Gottlieb, Griffiths, Gupta, Honda, Kurd, Lernia, Lernia, López-Ferrer, Lümig, Menter, Menter, Menter, Mrowietz, Nestle, Ortonne, Papoutsaki, Papp, Papp, Papp, Papp, Salvarani, Sbidian, Simone, Strober, Talamonti, Talamonti, Talamonti, Vandenbroucke, Vollenhoven   +40 more
core   +1 more source

Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis

Frontiers in Pharmacology, 2021
Psoriasis is a chronic inflammatory disease characterized by erythematous scaly plaques, accompanied by systemic damage that leads to the development of multiple comorbidities.
Jiangluyi Cai, Jiangluyi Cai, Lian Cui, Lian Cui, Yu Wang, Yu Wang, Ying Li, Ying Li, Xilin Zhang, Xilin Zhang, Yuling Shi, Yuling Shi   +11 more
doaj   +1 more source

The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis [PDF]

, 2010
Background: Acute generalized exanthematous pustulosis (AGEP) represents a severe, acute, pustular skin reaction that is most often induced by drugs. AGEP can be difficult to differentiate from generalized pustular psoriasis (GPP) both clinically and ...
Austin, Baker, Beylot, Beylot, Britschgi, Burrows, Farber, Friedman, Guevara-Gutierrez, Horn, Iizuka, Kardaun, Katz, Keller, Kingery, Macmillan, Mobini, Muller, Naldi, Roujeau, Roujeau, Schaefer, Schmid, Shelley, Shelley, Sidoroff, Sidoroff, Smith, Spencer, Staughton, Terui, Weedon, Weedon, Yawalkar, Zelickson   +34 more
core   +3 more sources

Development of bullous pemphigoid during treatment of psoriasis with ustekinumab: a case report and literature review

Frontiers in Medicine, 2023
Ustekinumab is a biological therapy that has been approved for treating moderate-to-severe psoriasis. Although injection site reactions, nasopharyngitis, headaches, and infections are the common adverse events associated with ustekinumab, the development
Luyang Kong, Luyang Kong, Dawei Huang, Dawei Huang, Jiajing Lu, Jiajing Lu, Yuexin Zhang, Yuexin Zhang, Ying Li, Ying Li, Xuemei Yi, Xuemei Yi, Yuling Shi, Yuling Shi   +13 more
doaj   +1 more source

Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis

Frontiers in Medicine, 2023
BackgroundRandomized controlled trials indicated guselkumab, the first anti-interleukin-23 monoclonal antibody, is efficacious in plaque psoriasis. However, guselkumab's performance in real life is scarcely examined, especially in China.ObjectivesThis ...
Jianfeng Zheng, Jianfeng Zheng, Wenjuan Chen, Wenjuan Chen, Xuemei Yi, Xuemei Yi, Ning Yu, Ning Yu, Yangfeng Ding, Yangfeng Ding, Yunlu Gao, Yunlu Gao   +11 more
doaj   +1 more source

Clinical consequences of antibody formation, serum concentrations, and HLA-Cw6 status in psoriasis patients on Ustekinumab [PDF]

, 2019
Background: Ustekinumab for the treatment of psoriasis is currently administered in a standard dosing regimen. However, some patients tend to benefit from alternative dosing regimens, a step toward personalized medicine.
Busard, Celine, I, Costanzo, Antonio, De Keyser, Eline, Hutten, Barbara A., Lambert, Jo, Lanssens, Sven, Meuleman, Lieve, Spuls, Phyllis, I, van den Reek, Juul M., Zweegers, Jeffrey   +9 more
core   +1 more source

Microarray analyses demonstrate the involvement of type i interferons in psoriasiform pathology development in D6-deficient mice [PDF]

, 2013
The inflammatory response is normally limited by mechanisms regulating its resolution. In the absence of resolution, inflammatory pathologies can emerge, resulting in substantial morbidity and mortality.
Baldwin, H.M., Carballido, J.M., Graham, G.J., Jamieson, T., Jaritz, M., King, V., McKimmie, C.S., Nibbs, R.J.B., Pallas, K., Rot, A.   +9 more
core   +1 more source

Efficacy of ω-3 supplementation in patients with psoriasis:a meta-analysis of randomized controlled trials [PDF]

, 2019
Several studies have been conducted with the aim of investigating the effect of Omega(Ï )-3 on different psoriasis indices including Psoriasis Area and Severity Index (PASI) score, erythema, scaling, itching, area involved, and infiltration. Nevertheless,
Clark, Cain, Jafarnejad, Sadegh, Nahavandi, Mina, Taghizadeh, Mohsen   +3 more
core   +2 more sources

Janus kinase inhibitors in autoimmune bullous diseases

Frontiers in Immunology, 2023
Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins.
Dawei Huang, Dawei Huang, Yuexin Zhang, Yuexin Zhang, Luyang Kong, Luyang Kong, Jiajing Lu, Jiajing Lu, Yuling Shi, Yuling Shi   +9 more
doaj   +1 more source

Cytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives To investigate the value of cytokine, chemokine, and neurofilament light chain (NfL) concentrations in predicting relapse risk, chronic epilepsy, and functional impairment in LGI1 autoimmune encephalitis (AE). Methods Cytokines/chemokines (IL‐1‐beta, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8/CXCL8, IL‐10, IL‐12p70, IL‐13, IL‐17A, GM‐CSF, TNF ...
Albert Aboseif, Georgios Mangioris, Binxia Yang, Vanessa K. Pazdernik, Jeffrey W. Britton, Divyanshu Dubey, Eoin P. Flanagan, Sarosh R. Irani, Gregory S. Day, Charles L. Howe, A. Sebastian López‐Chiriboga, Andrew McKeon, John R. Mills, Yahel Segal, Michel Toledano, Ivana Vodopivec, Sean J. Pittock, Anastasia Zekeridou   +17 more
wiley   +1 more source